Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Evogene (EVGN) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Evogene (EVGN) over the last 14 years, with Q3 2025 value amounting to $2.9 million.

  • Evogene's Operating Expenses fell 5649.74% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year decrease of 3742.4%. This contributed to the annual value of $22.0 million for FY2024, which is 2776.14% down from last year.
  • According to the latest figures from Q3 2025, Evogene's Operating Expenses is $2.9 million, which was down 5649.74% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, Evogene's Operating Expenses registered a high of $8.7 million during Q4 2021, and its lowest value of $2.9 million during Q3 2025.
  • Its 5-year average for Operating Expenses is $6.6 million, with a median of $7.4 million in 2023.
  • As far as peak fluctuations go, Evogene's Operating Expenses skyrocketed by 9146.64% in 2023, and later plummeted by 5649.74% in 2025.
  • Quarter analysis of 5 years shows Evogene's Operating Expenses stood at $8.7 million in 2021, then plummeted by 53.32% to $4.1 million in 2022, then surged by 91.47% to $7.8 million in 2023, then tumbled by 30.55% to $5.4 million in 2024, then plummeted by 46.91% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $3.8 million for Q2 2025, and $5.0 million during Q1 2025.